Merck halts small cell lung cancer immunotherapy drug trial
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated
Drugs
Health
Pharma
Drugs
Health
Pharma
Novartis’s drug to treat rare kidney disease gets USFDA approval
Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of
Drugs
Health
Pharma
Denmark’s Pharmacosmos to buy G1 Therapeutics for $405 million
Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.
Drugs
Health
Pharma
WHO: 40 athletes participating in Olympic Games test Covid-19 positive
The WHO’s event-based surveillance system has reported that at least 40 athletes participating in the Olympic Games in France had tested positive for
Drugs
Health
Pharma
Scientists inject goo in sheep’s knee joints to regenerate cartilage
Scientists at Northwestern University's Simpson Querrey Institute for BioNanotechnology have invented a bioactive material to successfully regenerate cartilage in the knee joints of
Drugs
Health
Pharma
France’s Servier gets FDA green light for oral drug to treat brain cancer
Servier Pharmaceuticals, the US arm of a French pharmaceutical company, got approval from the US drug regulator for a once-daily pill to treat
Drugs
Health
Pharma
Daiichi Sankyo to pay Merck $170 million for cancer test drug rights
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for
Drugs
Health
Pharma
Scientists develop potential compound to neutralise flesh-eating bacteria
A family of antimicrobial compounds can neutralise necrotising fasciitis, a deadly bacterial skin infection that is also known as flesh-eating disease, when tested
Drugs
Health
Pharma
New cardiovascular risk calculator may impose a burden on 16 million US citizens
HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the
Drugs
Health
Pharma
Contineum’s test drug may reverse multiple sclerosis damage
Contineum Therapeutics, Inc., a US San Diego-headquartered biopharmaceutical company’s trial drug may reverse multiple sclerosis damage by potentially restoring movement and function.